RTW Investments’s Orchestra BioMed OBIO Stock Holding History

RTW Investments’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$35.3M	Hold	8,306,063	–	–	0.35%	49
2025 Q4	$34.5M	Hold	8,306,063	–	–	0.35%	55
2025 Q3	$20.6M	Buy	8,306,063 +1	+0%	+$3	0.25%	55
2025 Q2	$22.3M	Buy	8,306,062 +99,900	+1%	+$292K	0.32%	46
2025 Q1	$35.1M	Hold	8,206,162	–	–	0.54%	35
2024 Q4	$32.8M	Buy	8,206,162 +3	+0%	+$16	0.5%	39
2024 Q3	$42.2M	Buy	8,206,159 +2,585,519	+46%	+$16.9M	0.61%	38
2024 Q2	$45.8M	Hold	5,620,640	–	–	0.71%	34
2024 Q1	$29.6M	Hold	5,620,640	–	–	0.44%	46
2023 Q4	$51.3M	Hold	5,620,640	–	–	0.8%	33
2023 Q3	$49M	Hold	5,620,640	–	–	1.03%	25
2023 Q2	$39.3M	Buy	5,620,640 +502,133	+10%	+$7.62M	0.75%	30
2023 Q1	$100M	Buy	5,118,507 +4,118,507	+412%	+$47.7M	2.09%	18
2022 Q4	$9.98M	Hold	1,000,000	–	–	0.2%	47
2022 Q3	$9.9M	Buy	+1,000,000	New	+$9.91M	0.23%	55

Other funds holding OBIO

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

DMKJ

David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return

RTW Investments's OBIO Position: Q1 2026 in Review

RTW Investments held its Orchestra BioMed (OBIO) position steady in Q1 2026 at 8,306,063 shares worth $35.3M. The position accounts for 0.35% of the portfolio, ranked #49.

RTW Investments first reported a position in OBIO in Q3 2022 and has held it in 15 quarters since. The position peaked at $100M in Q1 2023. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

RTW Investments held 8,306,063 shares of Orchestra BioMed worth $35.3M as of Q1 2026.
RTW Investments left its Orchestra BioMed share count unchanged in Q1 2026.
Orchestra BioMed made up 0.35% of RTW Investments's portfolio in Q1 2026, its #49 holding.
RTW Investments first reported a position in Orchestra BioMed in Q3 2022 and has held it in 15 quarters since.
RTW Investments's Orchestra BioMed position peaked at $100M in Q1 2023.
65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on RTW Investments's 13F filing for Q1 2026, filed 15 May 2026.